Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study
Saved in:
| Published in: | Breast Cancer : Targets and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867301676056051712 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Breast Cancer : Targets and Therapy |
| description | |
| discipline_display | Oncology |
| discipline_facet | Oncology |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:61094 |
| institution | FRELIP |
| journal_source_facet | Breast Cancer : Targets and Therapy |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study Oncology General Oncology |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Oncology General Oncology Oncology General Oncology |
| subject_facet | Oncology General Oncology |
| title | Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study |
| title_auth | Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study |
| title_full | Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study |
| title_fullStr | Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study |
| title_full_unstemmed | Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study |
| title_short | Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study |
| title_sort | capecitabine versus paclitaxel after cdk4/6 inhibitor progression in hormone receptor–positive, her2-negative metastatic breast cancer: a real-world study |
| topic | Oncology General Oncology |
| url | https://www.dovepress.com/capecitabine-versus-paclitaxel-after-cdk46-inhibitor-progression-in-ho-peer-reviewed-fulltext-article-BCTT |